Wordt geladen...
Pathologic response after neoadjuvant chemotherapy in resectable non-small cell lung cancers: proposal for the use of “major pathologic response” as a surrogate endpoint
Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials in this disease using overall survival as the primary endpoint require a decade or longer to complete, are expensive, and limit innovation. A surrogate for survival, such as pathologic response to neoa...
Bewaard in:
| Gepubliceerd in: | Lancet Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734624/ https://ncbi.nlm.nih.gov/pubmed/24384493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70334-6 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|